solutions@vitroscan.com
solutions@vitroscan.com

VitroScan at SITC 2025: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Download

VitroScan at ENA 2025: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Download

VitroScan at ESMO 2025: Chemo Sensitivity Score using an ex vivo 3D micro-tumor testing platform to predict clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

Download

VitroScan at FOB 2025: Ex vivo 3D micro-timor platform reveals patient-specific responses to bispecific antibodies and antibody-drug-conjugates

Download

Home Insights Scientific Posters archive